Prosensa Holding NV (NASDAQ:RNA) on Apr. 8 announced that Michael S. Wyzga has been nominated for appointment to its Supervisory Board at the next shareholders’ meeting, scheduled for June 17, 2014. Mr. Wyzga most recently served as President and Chief Executive Officer of Radius Health. Prior to joining Radius, Mr. Wyzga was Executive Vice President and Chief Financial Officer of Genzyme Corporation until its $20.1 billion acquisition by Sanofi in April 2011. Prosensa Holding NV (NASDAQ:RNA) shares after opening at $5.81 moved to $6.50 on last trade day and at the end of the day closed at $6.20. Company price to sales ratio in past twelve months was calculated as 17.67 and price to cash ratio as 1.85. Prosensa Holding NV (NASDAQ:RNA) showed a positive weekly performance of 22.29%.
Stemline Therapeutics, Inc. (NASDAQ:STML) announced on 10 April that the U.S. Food and Drug Administration (FDA) has accepted the company’s Investigational New Drug (IND) application for SL-701, which enables the company to advance SL-701 into a Phase 2 trial of adults with glioblastoma multiforme (GBM) in first recurrence. Stemline Therapeutics Inc. (NASDAQ:STML) shares fell -8.95% in last trading session and ended the day on $14.85. STML return on equity ratio is recorded as -50.10% and its return on assets is -47.00%. Stemline Therapeutics Inc. (NASDAQ:STML) yearly performance is 13.36%.
Cerulean Pharma Inc. (NASDAQ:CERU) announced on 15 April the closing of its initial public offering of 8.50 million shares of its common stock at a public offering price of $7.00 per share, before underwriting discounts. Cerulean Pharma Inc. (NASDAQ:CERU) shares moved down -1.34% in last trading session and was closed at $6.65, while trading in range of $6.28 – $7.14. Cerulean Pharma Inc. (NASDAQ:CERU) year to date (YTD) performance is -2.92%.
On April 17, 2014, Ambient Corporation (NASDAQ:AMBI) received a letter from the Listing Qualifications Department of the Nasdaq Stock Market indicating that the Company no longer complies with the minimum stockholders’ equity requirement for continued listing on the Nasdaq Capital Market. Ambit Biosciences Corp (NASDAQ:AMBI) weekly performance is -6.92%. On last trading day company shares ended up $6.46. Ambit Biosciences Corp (NASDAQ:AMBI) distance from 50-day simple moving average (SMA50) is -32.36%. Analysts mean target price for the company is $15.50.